Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%
HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

At a Glance

Live Snapshot
Market Cap$467.87M
EPS-1.4500
P/E Ratio-4.40
Earnings Date08/06/2026

rlmd

Net Cash Provided by Financing Activities

Last Annual Value

93.56M

3-Year CAGR

28%

5-Year CAGR

27%

10-Year CAGR

80%

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

RLMD · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
93.56M
N/A-13.0%N/A 
-336.00K
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.25M
583.2%-20.9%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.24M
-34.7%-49.2%N/A
75.89M
531.7%N/AN/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
11.52M
-35.1%-15.7%N/A
6.03M
-53.1%-44.0%N/A
9.00K
-92.8%-85.7%N/A
95.16M
160.4%6.2%N/A
24.82M
-43.3%-31.5%N/A
44.00K
-93.2%-57.7%-13.0%
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Fair Value Envelope

RLMD · NASDAQ

Our analysis suggests that RLMD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.38, this represents a potential HIDDEN relative to our calculated worth for Relmada Therapeutics, Inc..

Intrinsic Value
Current Price: $6.38